VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed incurable relapsed or refractory solid tumor or non-Hodgkin's lymphoma that has been treated on MSKCC-01131
• •Must have completed participation in protocol MSKCC-01131 through visit 16 and have shown evidence of stable disease or complete or partial remission of tumor burden and no evidence of symptomatic deterioration
• •* No adverse event or toxicity which resulted in discontinuation of participation in protocol MSKCC-01131
• •* If a patient experienced dose-limiting toxicity, then the patient must have demonstrated the ability to tolerate the same dose or a lower dose prior to entry in this study
• •No known or suspected squamous cell carcinoma of the lung
• •No prior or concurrent new neurological symptoms or CNS (brain or leptomeningeal) metastases during protocol MSKCC-01131
• •PATIENT CHARACTERISTICS:
• •Age
• •25 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •WBC at least 3,500/mm3
• •Absolute neutrophil count at least 1,500/mm3
• •Platelet count at least 100,000/mm3
• •Hemoglobin at least 9.0 g/dL
• •No severe or uncontrolled hematologic condition
• •Hepatic
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• •AST and ALT no greater than 2 times ULN
• •Alkaline phosphatase no greater than 2 times ULN
• •PT, PTT, and INR normal
• •Renal
• •Creatinine no greater than ULN
• •No 1+ or greater proteinuria
• •No severe or uncontrolled renal condition
• •Cardiovascular
• •No severe or uncontrolled cardiovascular condition
• •Pulmonary
• •No severe or uncontrolled pulmonary condition
• •Other
• •No prior hypersensitivity reactions to any recombinant proteins (e.g., VEGF Trap)
• •No severe or uncontrolled gastrointestinal, immunological, or musculoskeletal condition
• •No severe or uncontrolled psychiatric condition or adverse social circumstance that would preclude study
• •No other condition that would preclude study
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective double-barrier contraception during and for at least 3 months after study
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)
• •No other concurrent immunotherapy
• •Chemotherapy
• •No concurrent standard chemotherapy
• •Endocrine therapy
• •No concurrent adrenal corticosteroids except low doses as replacement therapy in patients who have previously received suppressive doses or for adrenal insufficiency
• •No concurrent systemic hormonal contraceptive agents
• •Radiotherapy
• •No concurrent radiotherapy
• •Surgery
• •Not specified
• •Other
• •At least 30 days since prior investigational therapy other than VEGF Trap
• •No concurrent standard or other investigational anticancer agents
• •No concurrent herbal supplements ("nutraceuticals")
• •No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, aspirin, or other nonsteroidal anti-inflammatory drugs) except selective cyclo-oxygenase-2 (COX-2) inhibitors for analgesia
• •No concurrent COX-2 inhibitors for tumor treatment or prophylaxis